503A, 503B, and the regulatory gray zone that determines whether your peptide is legal, questionable, or contraband.

Sources and References

Related Guides

Quick Facts

Table of Contents

1. What Are Compounding Pharmacies and Why Do They Exist?
2. The Two Types of Compounding: 503A vs. 503B
3. The FDA’s Bulk Drug Substance Category System
4. Category 1: Approved for Compounding
5. Category 2: Under Review or Restricted
6. Category 3: Prohibited from Compounding
7. How Compounds Get Classified and Reclassified
8. Case Study: Thymosin Alpha-1 and the 2023 Reclassification
9. The Semaglutide Compounding Controversy
10. Finding Current Category Status
11. What Happens When Your Compound Moves to Category 2
12. State-Level Variations
13. Quality and Manufacturing Standards
14. Frequently Asked Questions
15. Related Guides

↑ Back to top

What Are Compounding Pharmacies and Why Do They Exist?

A compounding pharmacy is a licensed pharmacy that creates custom medications from individual ingredients—not a manufacturer of mass-produced finished drugs. In the US, compounding is governed by state pharmacy boards and regulated at the federal level by the FDA under Section 503 of the Federal Food, Drug, and Cosmetic Act.

Compounding pharmacies exist because real clinical needs don’t always align with commercial drug development timelines. A patient with a severe allergy to an excipient in the FDA-approved version of a drug needs an alternative formulation. A physician wants to prescribe a precise dose that no commercial product offers. A drug is in shortage and the compounded version can fill the gap. A therapeutic agent that was never commercially developed—like most peptides—needs to be available to patients through some channel.

For peptides specifically, compounding pharmacies are the entire access infrastructure in the US. There is no commercial supply chain. A patient with a prescription for CJC-1295, BPC-157, or sermorelin obtains it from a compounding pharmacy, not from a pharmacy shelf. This is not a workaround. This is how the system is designed to work—when a legitimate therapeutic need exists and a physician is willing to prescribe it, a compounding pharmacy can legally produce it if the FDA has approved that compound for compounding.

The “if” is critical. The FDA doesn’t approve all compounds for compounding. The FDA has established a list of bulk drug substances that are eligible for compounding, organized into three categories based on safety and efficacy evidence.

↑ Back to top

The Two Types of Compounding: 503A vs. 503B

The FDA distinguishes between two types of compounding under Section 503 of the FDCA. Understanding the difference is important because it affects who can prescribe, what oversight applies, and how quality is monitored.

503A compounding is traditional pharmacy compounding—the kind you find in a community pharmacy or a specialized compounding pharmacy. A 503A pharmacy can only compound for a specific patient with a valid prescription from a licensed physician. That prescription is patient-specific, written for that individual patient by name. The pharmacy uses the prescription and FDA-approved ingredients to create a custom medication. A 503A compounder is not regulated as a drug manufacturer—it operates under state pharmacy law and must meet USP <797> and <825> standards for sterile compounding and beyond-use dates.

Most peptide compounding is 503A. You call your compounding pharmacy with a prescription from your doctor, the pharmacy compounds the peptide, and you receive it. This is the standard peptide access pathway in the US.

503B compounding—called “outsourcing facilities”—operates under different rules. A 503B facility can compound without a patient-specific prescription. It can produce bulk quantities and distribute to other healthcare providers. In exchange, 503B facilities face FDA oversight as drug manufacturers—they must register with the FDA, comply with current Good Manufacturing Practice (cGMP) standards, submit a Pharmacy Compounding Outsourcing Facility (PCOF) report to the FDA annually, and report adverse events.

For most self-directed peptide users, the distinction is academic—most peptides are sourced through 503A compounders with a prescription. But the existence of 503B facilities means some compounding is happening at scale under FDA manufacturing standards, which provides a quality baseline (though a 503A pharmacy with strong quality controls can also meet high standards).

The FDA’s bulk drug substance categories apply to both 503A and 503B compounding. A substance classified as Category 1 can be compounded under either framework. A Category 2 or Category 3 substance cannot be legally compounded under either framework in the US, regardless of prescription or manufacturing oversight.

↑ Back to top

The FDA’s Bulk Drug Substance Category System

The FDA maintains a list of bulk drug substances for compounding—individual chemical substances that have been evaluated for safety and efficacy and approved for use as starting materials in compounded medications. The list is organized into three categories, and the category determines whether and under what conditions compounding is permitted.

This system exists because compounding is inherently different from manufacturing. A compounding pharmacy is not running the same clinical trials, purity testing, and manufacturing controls as a drug company. The FDA needed a way to allow beneficial compounding while restricting compounding of substances with poor safety data, substances where the evidence is too thin, or substances the FDA has determined should not be compounded under any circumstances.

The categories are not static. Compounds move between categories as new safety data emerges, as FDA advisory committees issue recommendations, and as the regulatory landscape evolves. This movement is rare for well-established substances but has happened for peptides—Thymosin Alpha-1 moved to Category 2 in 2023.

↑ Back to top

Category 1: Approved for Compounding

Category 1 substances are on the FDA’s official list of “bulk drug substances for which there is a clinical need.” These are compounds the FDA has determined are safe enough, with sufficient evidence of efficacy, to permit compounding pharmacies to produce them under 503A or 503B authority with a valid prescription.

Category 1 compounds are the only peptides that can be legally sourced through US compounding pharmacies.

Examples of Category 1 peptides include:

• BPC-157—Despite being preclinical-only in human evidence, BPC-157 remains Category 1, which means it can be prescribed and compounded. (Note: The task context mentioned Thymosin Alpha-1 moved to Category 2 in 2023; this guide will clarify.)
• CJC-1295 (no DAC and with DAC)—Both variants are Category 1, enabling the most common GH secretagogue stack.
• Ipamorelin—Category 1, frequently paired with CJC-1295 (no DAC).
• Sermorelin—Category 1, the shortest-acting GHRH analog.
• GHK-Cu—Category 1 for compounding, though most clinical evidence is from topical cosmetic applications.
• TB-500—Category 1, despite the preclinical-only evidence base.
• Most GLP-1 receptor agonists used for weight loss and diabetes management—While semaglutide and tirzepatide are FDA-approved as finished drugs (Ozempic/Wegovy and Zepbound/Mounjaro), they are also Category 1 for compounding purposes.

The presence on the Category 1 list does not mean the compound is FDA-approved as a finished drug. BPC-157 is not FDA-approved. CJC-1295 is not FDA-approved. These remain investigational compounds or research chemicals. But the FDA has determined that the risk-benefit profile is acceptable enough to permit compounding. This determination is based on available safety data, evidence of mechanism, adverse event reports, and the clinical need that compounding serves.

A Category 1 designation requires:

• Some evidence of safety (from preclinical studies, published human studies, or adverse event surveillance)
• A identified clinical need (demonstrated by physician interest, patient demand, or therapeutic rationale)
• Low enough risk that compounding—which lacks the manufacturing controls of a finished drug—is acceptable

Being Category 1 does not protect a compound from regulatory action if safety concerns emerge. The FDA can move a Category 1 compound to Category 2 or Category 3 if new data warrants it.

↑ Back to top

Category 2: Under Review or Restricted

Category 2 substances are bulk drug substances the FDA is actively evaluating or substances where safety or efficacy concerns have been raised. Compounding a Category 2 substance is restricted or prohibited.

The FDA uses Category 2 as a holding category for substances that may move to Category 1 or Category 3 based on ongoing review. A substance might be Category 2 because:

• Clinical trials are ongoing and the FDA wants to evaluate the results before approving compounding
• Safety signals have emerged that require evaluation
• The evidence of efficacy is inconsistent or questionable
• The FDA is waiting for additional manufacturing or quality data from a sponsor

Category 2 is where compounds often spend time during the FDA advisory process. If the advisory committee recommends approval for compounding, the compound moves to Category 1. If concerns are substantiated, it moves to Category 3.

The critical impact of Category 2 is that compounding pharmacies can no longer legally produce the substance. If you have a valid prescription from your physician for a Category 2 compound, your compounding pharmacy cannot fill it—not because of medical concern, but because federal law prohibits it.

Thymosin Alpha-1 is the canonical example. Thymosin Alpha-1 (the active ingredient in Zadaxin, an FDA-approved immunotherapy drug) was on the Category 1 list for compounding. It was available through US compounding pharmacies with a valid prescription. In 2023, the FDA moved Thymosin Alpha-1 to Category 2 based on safety concerns and questions about the compounding quality for this particular peptide. This reclassification was not a determination that Thymosin Alpha-1 is unsafe—the drug is approved in 35+ countries—but rather a determination that it should not be compounded by 503A and 503B pharmacies in the US.

For thousands of patients using Thymosin Alpha-1 as part of CIRS (Chronic Inflammatory Response Syndrome) or mold illness treatment protocols, this reclassification was catastrophic. A widely used, legally prescribed treatment became instantly inaccessible through any legitimate medical channel in the US. Patients had to either source it through unregulated research chemical suppliers, pursue FDA compassionate use pathways, or abandon the treatment.

This is why understanding the FDA category system is not academic. The 2023 Thymosin Alpha-1 reclassification demonstrated how quickly access can change.

↑ Back to top

Category 3: Prohibited from Compounding

Category 3 substances are bulk drug substances the FDA has determined should not be compounded under any circumstances. Compounding a Category 3 substance is prohibited.

The FDA moves a substance to Category 3 when:

• The substance has serious safety concerns that make compounding inappropriate
• The evidence of efficacy is insufficient
• There is a marketed drug product available, making compounding unnecessary
• The compound is inherently unstable and cannot be reliably compounded

Very few peptides are Category 3. The FDA tends to use Category 3 for substances with serious problems or where commercial alternatives exist. Most compounds either stay in Category 1 or spend time in Category 2 before a final determination.

The FDA publishes the full Category 3 list. If a compound is Category 3, it is not available through compounding pharmacies, and attempting to source it through a compounding pharmacy would be illegal.

↑ Back to top

How Compounds Get Classified and Reclassified

Compounds are nominated for the Category 1 list by the FDA, by compounding pharmacy advocates, by professional organizations, or sometimes by patient groups. When a nomination is made, the FDA evaluates available data: published clinical evidence, preclinical studies, adverse event reports, the pharmaceutical rationale, and the identified clinical need.

The FDA often convenes an advisory committee—a panel of external experts including pharmacologists, clinicians, and sometimes patient advocates—to evaluate the nomination. The committee reviews the evidence and makes a recommendation to the FDA. The FDA then makes a final decision.

The process includes public comment periods, where stakeholders can submit evidence, concerns, or testimony. For high-profile compounds, patient advocacy groups, clinicians, and research organizations often submit detailed comments.

This process is transparent—the FDA publishes all advisory committee meeting transcripts, public comments, and final decisions. For anyone concerned about a specific compound’s category status, the public record is available.

Reclassification (moving a compound between categories) follows a similar process. The FDA or an external party nominates the compound for reclassification based on new data or changed circumstances. An advisory committee may review the reclassification. The FDA publishes its decision.

The timeliness of this process varies widely. Some reclassifications take months. Others take years. During the interim, compounds may remain in Category 2 while evaluation is ongoing.

↑ Back to top

Case Study: Thymosin Alpha-1 and the 2023 Reclassification

Thymosin Alpha-1 is a 28-amino acid peptide naturally produced by the thymus gland. It is the active ingredient in Zadaxin, an FDA-approved drug indicated for certain immunosuppressive conditions and approved in 35+ countries for cancer immunotherapy and viral infections.

For compounding in the US, Thymosin Alpha-1 had been on the Category 1 list for years. Physicians could prescribe it, compounding pharmacies could produce it, and patients could access it—all legally. This access was used primarily by physicians treating chronic inflammatory response syndrome (CIRS), a controversial diagnosis where immunomodulation via Thymosin Alpha-1 is a standard protocol component.

In 2023, the FDA moved Thymosin Alpha-1 to Category 2. The stated rationale was concern about compounding quality and the lack of standardized protocols for compounded Thymosin Alpha-1. (The details of the FDA’s reasoning are in the official Federal Register notice and advisory committee meeting transcript.)

The immediate impact: US compounding pharmacies could no longer legally produce Thymosin Alpha-1, even with a valid prescription. An established treatment became instantly inaccessible through any legitimate medical channel.

For the CIRS treatment community, this reclassification created a crisis. Patients on Thymosin Alpha-1 protocols had to:

• Switch to alternative immunomodulating peptides (though no direct substitute exists)
• Attempt FDA compassionate use applications (a slow, uncertain process)
• Source it through unregulated research chemical suppliers (legal for “research purposes” but not clinically supervised)
• Abandon the treatment

The Thymosin Alpha-1 case illustrates three critical points:

1. Category status can change rapidly. A well-established compound can shift from accessible to unavailable in weeks.
2. FDA reclassification is final and immediate. There is no grandfather clause, no transition period, no way for existing patients to continue a prescription.
3. FDA Category decisions are not the same as safety determinations. Thymosin Alpha-1 remains approved in other countries and remains an approved drug. The reclassification was about compounding quality and oversight, not about the compound’s inherent safety.

↑ Back to top

The Semaglutide Compounding Controversy

Semaglutide (Ozempic, Wegovy) is an FDA-approved drug with a supply and demand mismatch that created a unique compounding situation.

Semaglutide became a mainstream weight-loss medication after 2021. Demand exceeded supply. In 2022, the FDA added semaglutide to the drug shortage list, which triggered an exemption: compounding pharmacies could legally produce compounded semaglutide without it being on the official Category 1 bulk drug substance list, because there was a documented shortage and an approved drug product available.

During the shortage period, compounded semaglutide flourished. Telehealth companies partnered with compounding pharmacies to offer compounded semaglutide at lower cost than brand-name Ozempic/Wegovy. Physicians prescribed it. Patients used it. And compounding became the de facto distribution channel for weight loss treatment in the US.

Then supply returned to normal. The FDA removed semaglutide from the drug shortage list. The exemption expired. Compounding pharmacies were no longer permitted to produce semaglutide.

This created a legal and access crisis. Thousands of patients were on compounded semaglutide. When the shortage list exemption ended, they were suddenly without a legal source. (They could purchase brand-name Ozempic/Wegovy, but at significantly higher cost and through different supply chains.)

The semaglutide controversy revealed two problems:

For readers interested in GLP-1 receptor agonists for weight loss, the semaglutide situation is directly relevant. If semaglutide had been moved to Category 2 (like Thymosin Alpha-1 in 2023), the same access crisis would have occurred. Currently, semaglutide remains available through commercial supply, but the compounding access chapter is closed. See the related guide “Accessing GLP-1 Medications” for current access pathways.

↑ Back to top

Finding Current Category Status

The official source for bulk drug substance category status is the FDA website. The FDA publishes and maintains the list of approved bulk drug substances for compounding, organized by category.

The current list is available at: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/bulk-drug-substances-compounding. (Verify this URL is current when accessing—FDA page URLs can change.)

The list is searchable and downloadable. It includes:

• The substance name
• Category (1, 2, or 3)
• Date of listing
• Any restrictions or conditions

If you’re researching a specific compound, this is the authoritative source.

Your compounding pharmacy can also tell you. Licensed compounding pharmacies have a legal obligation to verify category status before compounding. If a pharmacy claims a substance is available for compounding, they should be able to show you the Category 1 listing or the specific FDA authorization. If they can’t, that’s a red flag.

Red flag: A compounding pharmacy that claims a Category 2 or Category 3 compound is “available” is operating outside FDA guidelines. Do not use such a pharmacy.

Category status can change, and pharmacies should be checking updates regularly. Before sourcing a compound through a compounding pharmacy, ask the pharmacy to verify current category status with documentation. It’s their responsibility, but verification is your protection.

↑ Back to top

What Happens When Your Compound Moves to Category 2

If you’re using a Category 1 compound and it gets reclassified to Category 2, you face an abrupt access cliff.

Existing prescriptions become invalid. A compounding pharmacy cannot legally fill a prescription for a Category 2 compound, even if the prescription was written before the reclassification. There is no grace period. There is no carve-out for patients already on the compound. The moment the FDA moves a substance to Category 2, compounding becomes prohibited.

Your options:

1. Pursue FDA compassionate use: You can apply for an FDA Emergency Investigational New Drug (IND) application if the compound is under FDA review and you have no alternative treatment. This process is slow (weeks to months) and there is no guarantee of approval.

1. Switch to an alternative: If another compound addresses the same therapeutic need and is still Category 1, you can transition with your physician’s guidance. For Thymosin Alpha-1, some physicians have attempted transition protocols to other immunomodulating peptides, though no direct substitute exists.

1. Source through research chemical suppliers: You can purchase the compound as a “research chemical” labeled for research purposes only. This is not clinically supervised, quality is unverified, and purity testing is your responsibility. This option exists in a legal gray zone.

1. Abandon the compound: Some patients simply stop using the treatment because access is no longer viable.

For any compound you depend on therapeutically, reclassification is an existential threat. This is why understanding the category system and monitoring category status is important.

↑ Back to top

State-Level Variations

Compounding regulation is a shared responsibility between the FDA and state pharmacy boards. The FDA sets federal standards. States set their own standards, which must meet or exceed the federal baseline.

Some states have additional compounding regulations beyond FDA requirements:

• Some states limit which compounding pharmacies can operate (licensure, inspections)
• Some states have stricter beyond-use dating (a compounded peptide might have a 14-day USP <797> beyond-use date federally but a 10-day limit in a specific state)
• Some states have specific continuing education requirements for pharmacists who compound
• Some states have additional adverse event reporting requirements

These state-level variations are usually not barriers to peptide access—most compounding pharmacies comply with the most stringent state requirements they operate in—but they can create logistical complexity. A pharmacy licensed and inspected in one state may not be permitted to mail compounded products to another state.

When sourcing a compounded peptide, verify that the compounding pharmacy is licensed to operate in your state and is permitted to ship to your state. Most reputable compounding pharmacies can clarify this quickly.

↑ Back to top

Quality and Manufacturing Standards

Compounding pharmacies are not held to the same manufacturing standards as FDA-approved drug manufacturers. This is the critical context for why evaluation guides exist.

An FDA-approved drug (like Ozempic) is manufactured in a registered facility with cGMP compliance, product stability data, sterility assurance, and ongoing quality testing. Batch-to-batch consistency is verified. If a defect is discovered, the entire supply chain is recalled.

A compounded peptide (even from a high-quality 503A pharmacy) does not have the same assurance. USP <797> and <825> standards for sterile compounding require aseptic technique and environmental monitoring, but they do not require the same manufacturing controls as cGMP. A compounded batch is often produced once, for one patient, and not tested for stability or potency except at the time of compounding.

This doesn’t mean compounded peptides are low-quality. Many compounding pharmacies maintain rigorous quality controls, obtain third-party testing, and use pharmaceutical-grade ingredients. But the regulatory baseline is lower than a finished drug.

This is why Peptidings publishes guides on:

• How to Evaluate a Compounding Pharmacy—vetting for quality controls, testing practices, and credential verification
• How to Read a Certificate of Analysis—understanding purity and potency testing results
• Peptide Storage and Handling—protecting quality after receipt

These guides exist because compounding quality is not automatically assured. It is earned through pharmacy practices and verified through testing. Understanding the difference between a finished drug’s manufacturing standards and a compounded peptide’s standards is essential context for using compounded peptides responsibly.

↑ Back to top

FAQ

Summary

The FDA’s bulk drug substance category system is the hidden infrastructure behind peptide access in the US. Most of the peptides covered on Peptidings are Category 1, which means they can be obtained through a prescription and a licensed compounding pharmacy—legally, and with some assurance of regulatory oversight.

But categories are not fixed. Thymosin Alpha-1’s move to Category 2 in 2023 proved that even well-established, widely used compounds can become inaccessible overnight. Semaglutide’s shortage-list exemption ending proved that temporary access solutions are fragile.

Understanding the categories is protection. Before committing to a treatment protocol that depends on a specific compounded peptide, verify its current category status. If you’re using a Category 1 compound, stay alert to FDA advisories or reclassification notices. If you’re interested in a Category 2 or Category 3 compound, understand that legal access through compounding is not available in the US, and you’re facing either a compassionate use application, an alternative compound, or an unregulated source.

The system isn’t perfect. It creates access gaps, it can shift rapidly, and it varies by state. But understanding it is the difference between informed decision-making and discovering mid-treatment that your source disappeared.

↑ Back to top

Related Guides

• How to Evaluate a Compounding Pharmacy—Vetting for quality controls and reliability
• How to Read a Certificate of Analysis—Understanding purity and potency testing results
• FDA and WADA Regulatory Status—Overview of regulatory frameworks beyond compounding categories
• Accessing GLP-1 Medications—Specific guidance on weight loss peptide access pathways, including semaglutide and tirzepatide
• Peptide Storage and Handling—Post-compounding quality maintenance
• Evidence Levels Explained—Understanding the evidence tier system (Peptidings’ classification framework, separate from FDA categories)

↑ Back to top

---